ClinicalTrials.gg
Active, not recruitingNCT05450692LATIFYUpdated Jul 13, 2026

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

A Phase 3 interventional study of Ceralasertib and Durvalumab in Advanced or Metastatic Non-Small Cell Lung Cancer, sponsored by AstraZeneca. Active, not recruiting at 191 sites in 23 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
594
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca — 25 open to participants now, 78 under way, 28 of them phase 3. Carcinoma, Non-Small-Cell Lung · AstraZeneca.

Enrollment
27th of 137
594 · median 152
Started
2022
with 13 others
Phase 3
44 of 209
6 open now
Primary completion
2025-10
later than 24 of 77 live
Registered
161st of 209
by date

Among the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, this one is the 27th largest by enrollment of the 137 interventional ones that give a count, is one of 14 that started in 2022, is one of 44 in phase 3, reaches primary completion later than 24 of the 77 other live ones, and was the 161st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

25 of the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 25 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, or all of them as a file.
02

Study summary

This study will assess the efficacy and safety of the combination of ceralasertib and durvalumab versus standard of care docetaxel in patients with locally advanced and metastatic NSCLC after progression on prior anti-PD-(L)1 therapy and platinum-based chemotherapy.

Read the detailed description

This study will consist of two treatment arms (Groups A and B).

Participants will be randomised in a 1:1 ratio to one of the two treatment groups:

  • Group A: Ceralasertib plus durvalumab combination therapy Each 28-day cycle will begin with ceralasertib administered orally followed by durvalumab administered intravenously.
  • Group B: Docetaxel monotherapy Each 21-day cycle will begin with the administration of docetaxel.
03

Conditions studied

  • Advanced or Metastatic Non-Small Cell Lung Cancer

Keywords

  • Durvalumab
  • Ceralasertib
  • Docetaxel
  • Lung cancer
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically documented NSCLC that is locally advanced or according to Version 8 of the IASLC Staging Manual in Thoracic Oncology.
  • Documented epidermal growth receptor factor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type status as determined at a local laboratory.
  • Documented radiological PD whilst on or after receiving the most recent treatment regimen.
  • Eligible for second- or therapy and must have received an anti-PD-(L)1 therapy and a platinum doublet containing therapy for locally advanced or metastatic NSCLC either separately or in combination.
  • (ECOG)/World Health Organization (WHO) performance status of 0 or 1.
  • Adequate organ function and marrow reserve
  • Minimum of 12 weeks.
  • Body weight > 30 kg and no cancer-associated cachexia.
  • Negative pregnancy test (serum test) for women of (WOCBP).

Exclusion criteria

Exclusion Criteria:

  • Participant with mixed SCLC and NSCLC histology.
  • History of another primary except for malignancy treated with curative intent with no known active disease ≥ 5 years before the first dose of study intervention.
  • Persistent toxicities ( Grade > 2) caused by previous anticancer therapy.
  • Active or prior documented or inflammatory disorders.
  • Participants who have received more than one line of prior anti-PD-(L)1, either alone or in any combination.
  • Participants:

    1. Must not have experienced a toxicity that led to permanent discontinuation of the prior anti-PD(L)1 therapy.
    2. All AEs while receiving prior anti-PD(L)1 therapy must have completely resolved.
    3. Must not have experienced a Grade ≥ 3 immune-mediated adverse event (imAE) or an immune-related neurologic or ocular AE of any grade while receiving prior anti-PD(L)1 therapy.
    4. Must not have required the use of additional other than for the management of an AE, not have experienced recurrence of an AE if re-challenged, and not currently require maintenance doses of > 10 mg prednisone or equivalent per day.
  • Participants who have received more than one prior line of platinum-based chemotherapy in setting.
  • Participants who have received a prior ataxia telangiectasia and Rad3-related protein (ATR) inhibitor.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
594 participants (actual)

Study arms

  • Experimental
    Group A: Ceralasertib plus durvalumab combination therapy

    Participants will be administered ceralasertib orally followed by durvalumab administered intravenously.

    Drug: Ceralasertib · Drug: Durvalumab

  • Active comparator
    Group B: Docetaxel monotherapy

    Participants will be administered docetaxel (standard of care) administered intravenously.

    Drug: Docetaxel

Interventions

  • Participants will receive ceralasertib oral tablets.

  • Participants will receive durvalumab as an intravenous infusion.

  • Participants will received docetaxel as an intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    The superiority of ceralasertib plus durvalumab combination therapy relative to docetaxel will be demonstrated by assessment of OS (HR with 95% CI and p-value) in participants with advanced NSCLC after second- or third-line therapy and without actionable genomic alterations. OS is defined as time from randomisation until the date of death due to any cause.

    Time frame: Every 3 months (± 1 week) following objective progression of disease (PD) or treatment discontinuation (up to three years)

Secondary outcomes

  1. Progression-Free Survival (PFS)

    PFS will be defined as the time from the date of randomisation until the date of objective PD.

    Time frame: Up to 3 years

  2. Objective Response Rate (ORR)

    ORR is defined as the proportion of participant who have a Complete Response (CR) or Partial Response (PR) per RECIST 1.1.

    Time frame: Up to 3 years

  3. Duration of Response (DoR)

    DoR is defined as the time from the date of first documented response until date of documented progression per RECIST 1.1.

    Time frame: Up to 3 years

  4. Time To Response (TTR)

    TTR is defined as the time from randomisation until the date of first documented objective response.

    Time frame: Up to 3 years

  5. Disease Control Rate (DCR)

    DCR at 18 weeks is defined as the percentage of participants who have a CR or PR or who have stable disease (SD) for at least 17 weeks.

    Time frame: At Week 18

  6. Time to second progression or death (PFS2)

    Time from randomisation to PFS2 will be defined as the time from the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death.

    Time frame: Up to 3 years

  7. Overall Survival (OS) at 12 months

    OS is defined as time from randomisation until the data of death due to any cause.

    Time frame: At 12 months

  8. Time To Deterioration (TTD) of health-related quality of life (QoL)

    TTD is defined as the time from randomisation until the date of first confirmed deterioration.

    Time frame: Up to 3 years

  9. TTD of physical function

    TTD in physical functioning is measured by the EORTC QLQ-C30 Physical Function subscale of the EORTC QLQ-C30.

    Time frame: Up to 3 years

  10. Plasma concentrations for ceralasertib plus durvalumab combination therapy

    The PK plasma concentration of ceralasertib when administered in combination with durvalumab will be assessed.

    Time frame: Up to 3 years

  11. Number of participants with Adverse Evens (AEs)

    The safety and tolerability of ceralasertib plus durvalumab combination therapy as compared with docetaxel will be assessed.

    Time frame: Up to 3 years

07

Study locations

191 sites
  • Research Site
    Mobile, Alabama 36607, United States
  • Research Site
    Chandler, Arizona 85224, United States
  • Research Site
    Los Alamitos, California 90720, United States
  • Research Site
    Los Angeles, California 90017, United States
  • Research Site
    Whittier, California 90603, United States
  • Research Site
    Jacksonville, Florida 32256, United States
  • Research Site
    Orlando, Florida 32804, United States
  • Research Site
    Athens, Georgia 30607, United States
  • Research Site
    Atlanta, Georgia 30318, United States
  • Research Site
    Fort Wayne, Indiana 46804, United States
  • Research Site
    Baltimore, Maryland 21231, United States
  • Research Site
    Bethesda, Maryland 20817, United States
  • Research Site
    Rockville, Maryland 20852, United States
  • Research Site
    Hattiesburg, Mississippi 39401, United States
  • Research Site
    St Louis, Missouri 63110, United States
  • Research Site
    Omaha, Nebraska 68114, United States
  • Research Site
    Reno, Nevada 89511, United States
  • Research Site
    Charlotte, North Carolina 28204, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Canton, Ohio 44718, United States
  • Research Site
    Cleveland, Ohio 44106, United States
  • Research Site
    Allentown, Pennsylvania 18103, United States
  • Research Site
    York, Pennsylvania 17403, United States
  • Research Site
    Houston, Texas 77090, United States
  • Research Site
    Huntsville, Texas 77340, United States
  • Research Site
    Kingwood, Texas 77339, United States
  • Research Site
    Appleton, Wisconsin 54911, United States
  • Research Site
    Buenos Aires, 1058, Argentina
  • Research Site
    Pergamino, B2700CPM, Argentina
  • Research Site
    Rosario, S2000DSV, Argentina
  • Research Site
    Rosario, S2000KZE, Argentina
  • Research Site
    San Juan, 5400, Argentina
  • Research Site
    Elizabeth Vale, 5112, Australia
  • Research Site
    Lismore, 2480, Australia
  • Research Site
    Murdoch, 6150, Australia
  • Research Site
    South Brisbane, 4101, Australia
  • Research Site
    Wollongong, 2500, Australia
  • Research Site
    Charleroi, 6000, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Libramont-Chevigny, 6800, Belgium
  • Research Site
    Roeselare, 8800, Belgium
  • Research Site
    Fortaleza, 60810-180, Brazil
  • Research Site
    Porto Alegre, 90110-270, Brazil
  • Research Site
    Porto Alegre, 90610-000, Brazil
  • Research Site
    Salvador, 40170-110, Brazil
  • Research Site
    São Paulo, 01246-000, Brazil
  • Research Site
    São Paulo, 09323-900, Brazil
  • Research Site
    Vancouver, British Columbia VSZ 4E6, Canada
  • Research Site
    Newmarket, Ontario L3Y 2P9, Canada
  • Research Site
    Chicoutimi, Quebec G7H 7P2, Canada
  • Research Site
    Montreal, Quebec H2L 4M1, Canada
  • Research Site
    Montreal, Quebec H3G 1A4, Canada
  • Research Site
    Québec, Quebec G1V 4G5, Canada
  • Research Site
    Rimouski, Quebec G5L 5T1, Canada
  • Research Site
    Baoding, 071000, China
  • Research Site
    Beijing, 100021, China
  • Research Site
    Beijing, 100044, China
  • Research Site
    Changsha, 410008, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Deyang, 618000, China
  • Research Site
    Guangzhou, 510080, China
  • Research Site
    Hangzhou, 310009, China
  • Research Site
    Hefei, 230001, China
  • Research Site
    Jinan, 250013, China
  • Research Site
    Linyi, 276000, China
  • Research Site
    Nanchang, 330000, China
  • Research Site
    Nanjing, 210029, China
  • Research Site
    Nanning, 530021, China
  • Research Site
    Nashik, 422011, China
  • Research Site
    Qingdao, 266071, China
  • Research Site
    Taiyuan, 030000, China
  • Research Site
    Tianjin, 300052, China
  • Research Site
    Tianjin, 300060, China
  • Research Site
    Wuhan, 430000, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Wuhan, 430079, China
  • Research Site
    Zhanjiang, 524001, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Angers, 49933, France
  • Research Site
    Clamart, 92140, France
  • Research Site
    Clermont-Ferrand, 63011, France
  • Research Site
    Créteil, 94010, France
  • Research Site
    Lyon, 69373, France
  • Research Site
    Montpellier, 34070, France
  • Research Site
    Nantes, 44093, France
  • Research Site
    Paris, 75014, France
  • Research Site
    Pessac, 33604, France
  • Research Site
    Saint-Herblain, 44805, France
  • Research Site
    Saint-Quentin, 02321, France
  • Research Site
    Vantoux, 57070, France
  • Research Site
    Villefranche-sur-Saône, 69655, France
  • Research Site
    Villejuif, 94805, France
  • Research Site
    Berlin, 12351, Germany
  • Research Site
    Freiburg im Breisgau, 79106, Germany
  • Research Site
    Gauting, 82131, Germany
  • Research Site
    Karlsruhe, 76137, Germany
  • Research Site
    Kempten, 87439, Germany
  • Research Site
    Löwenstein, 74245, Germany
  • Research Site
    Moers, 47441, Germany
  • Research Site
    Hong Kong, 999077, Hong Kong

Showing the first 100 of 191 sites across 23 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Oct 2025, 36 months.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 36 months is close to that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2022
First posted
Jul 11, 2022
StartActual
Sep 15, 2022
Primary completionActual
Oct 6, 2025
CompletionEst.
Dec 31, 2027
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05450692
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Jul 11, 2022
Start date
Sep 15, 2022
Primary completion
Oct 6, 2025
Completion
Dec 31, 2027 (estimated)
Last update
Jul 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ceralasertib

Start the discussion